NQO1 antibody (C-Term)

Catalog No. ABIN374187

Product Details anti-NQO1 Antibody

Target: NQO1 (NAD(P)H Dehydrogenase, Quinone 1 (NQO1))

Binding Specificity: C-Term

Reactivity: Human, Mouse, Rat, Dog, Pig

Host: Goat

Clonality: Polyclonal

Conjugate: This NQO1 antibody is un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Sequence: C-SIPTDNQIKA RK

Specificity: This antibody is expected to recognize all three reported isoforms (NP_000894.1, NP_001020604.1 and NP_001020605.1) of NQO1.

Cross-Reactivity (Details): Species reactivity (expected):Rat, Pig.
Species reactivity (tested):Human, Mouse, Canine.

Purification: Ammonium Sulphate Precipitation followed by Antigen Affinity Chromatography using the immunizing peptide

Immunogen: Peptide from C Terminus of the protein sequence according to NP_000894.1, NP_001020604.1, NP_001020605.1. Genename: NQO1

Application Details

Application Notes: Peptide ELISA: Limit dilution 1: 64000. Western blot: 0.03-0.1 μg/mL. Approx.30 kDa band observed in Human Kidney and Lunglysates (calculated MW of 30.0 kDa according to NP_000894.1).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Tris saline, pH ~7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

References for anti-NQO1 antibody (ABIN374187)

Tanaka, Aleksunes, Cui, Klaassen: "ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling." in: Toxicological sciences : an official journal of the Society of Toxicology, Vol. 108, Issue 2, pp. 247-57, (2009) (PubMed).

Vincent, Kato, McLean, Soules, Feldman: "Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms." in: Antioxidants & redox signaling, Vol. 11, Issue 3, pp. 425-38, (2009) (PubMed).

Target Details for NQO1

Target: NQO1 (NAD(P)H Dehydrogenase, Quinone 1 (NQO1))

Alternative Name: NQO1 (NQO1 Products)

Synonyms: zgc:77191 antibody, wu:fb63c10 antibody, nqo1 antibody, DHQU antibody, DIA4 antibody, DTD antibody, NMOR1 antibody, NMORI antibody, QR1 antibody, Dia4 antibody, AV001255 antibody, Dtd antibody, Nmo-1 antibody, Nmo1 antibody, Nmor1 antibody, Ox-1 antibody, Ox1 antibody, Qr1 antibody, NADPH-d antibody, NAD(P)H dehydrogenase, quinone 1 antibody, NAD(P)H quinone dehydrogenase 1 antibody, NAD(P)H dehydrogenase, quinone 1 L homeolog antibody, nqo1 antibody, NQO1 antibody, Bpet2092 antibody, nqo1.L antibody, Nqo1 antibody

Background: NQO1 is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. NQO1's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. NQO1 functions as an important part of cellular antioxidant defense by detoxifying quinones thus preventing the formation of reactive oxygen species. Mutations in the gene for NQO1 have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of NQO1 has been seen in many tumors and is also associated with Alzheimer's disease (AD). NQO1 levels have been shown to be raised in may tumour types. This has led to a search for anti-tumour agents that can be activated by NQO1 resulting in specific targetting of these compounds to the tumour site. Many cytotoxic drugs contain the quinone moiety, such as the benzoquinone group, which can be activated by NQO1 through the reduction into hydroquinone [which in this case can auto-oxidize and lead to the formation of free radicals and alkylating species]. However, the rat enzyme has been shown to be significantly more effective in activating some of these compounds than the human and mouse enzymes. This indicates that the available cytotoxic drugs are better substrates for the rat enzyme and are not the most ideal prodrugs for activation by NQO1 in human tumors.Synonyms: Azoreductase, DIA4, DT-diaphorase, Menadione reductase, NAD(P)H dehydrogenase [quinone] 1, NAD(P)H:quinone oxidoreductase 1, NMOR1, Phylloquinone reductase, Quinone reductase 1

Gene ID: 1728

NCBI Accession: NP_000894

UniProt: P15559